MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease

  • STATUS
    Recruiting
  • End date
    Dec 25, 2022
  • participants needed
    240
  • sponsor
    University Hospital, Basel, Switzerland
Updated on 25 November 2021
ascites
hepatic failure
encephalopathy
acute on chronic liver failure
liver disease
cirrhosis
acute liver failure
liver failure
monocytes
hepatectomy
acute hepatic failure
Accepts healthy volunteers

Summary

This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure and to healthy controls.

Description

MER receptor tyrosine kinase (MERTK) signalling cascade becomes activated on monocytes/macrophages during disease progression of liver cirrhosis from Child Pugh A to B/C, corresponding to early stages of decompensation, and before the receptor expression is increased. Factors involved in activation of the MERTK signalling cascade might be microbial products such as bacterial deoxyribonucleic acid (DNA) and other toll-like receptor (TLR)-ligands, MERTK ligands and cytokines, as shown elevated in cirrhotic patients.

Given the observation that MERTK levels peak on the day of admission with organ failure and decrease in patients surviving the episode of acute-on-chronic liver failure (ACLF), MERTK Inhibition at a time during progression of cirrhosis but before manifestation of acute decompensation with no cirrhosis (AD) or ACLF might prevent infectious complications, decompensation and improve survival in patients with cirrhosis.

This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure and to healthy controls.

Details
Condition Cirrhosis, LIVER DISEASE, Hepatic Insufficiency, Hepatic Failure, Acute on Chronic Liver Failure, Hepatic Fibrosis, Liver Disorders, Liver Failure, hepatic disease, hepatopathy, liver diseases, hepatic diseases, hepatic pathology, hepatic cirrhosis, liver cirrhosis
Treatment Clinical data collection, blood sampling for research purpose, Health-related Questionnaires, Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
Clinical Study IdentifierNCT04116242
SponsorUniversity Hospital, Basel, Switzerland
Last Modified on25 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with compensated or decompensated chronic liver disease
Patients with acute- or acute-on-chronic chronic liver failure
Controls with no liver disease

Exclusion Criteria

Evidence of disseminated malignancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note